• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Competitor Analysis: Obesity & Diabetes Product Image

Competitor Analysis: Obesity & Diabetes

  • ID: 607789
  • March 2007
  • 72 Pages
  • La Merie Publishing

Product description The present Competitive Intelligence Report provides a competitor evaluation in the field of molecules used to treat diabetes as of March 2007. The competitor evaluation of Molecules to treat diabetes compiles parts of our Competitor Analysis Series which previously have been published in R&D Pipeline News, vol.3, 2007. Competitor projects are listed in a tabular format providing Information on:

Information is provided on:

Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

Chapter 1: Obesity

CB1
Selective 5-HT2c Receptor Agonists
Selective 5-HT6 Receptor Antagonists
Monoamine-related Mechanism of Action
Pro-opiomelanocortin (POMC) & Melanin-related Mechanism of Action
Protein tyrosine phosphatase-1B (PTP-1B) Inhibitors
PPAR Agonists
Thyroid Hormone Receptor Modulators
SGLT-2 Inhibitors
Microsomal triglyceride transfer protein inhibitors
Various
Anti-Obesity peptides
Anti-Obesity Biologics

Chapter II: Insulin

Insulin Market: Sales 2006
Inhaled Insulin
Nasal Insulin
Transdermal Insulin
Oral Insulin
Engineered Insulin
Long-Acting Insulin
Follow-On Insulin

Chapter III: PPAR Agonists

1st Generation PPAR Gamma Agonists
Next Generation PPAR Gamma Agonists
PPAR Alpha Agonists (Fibrate Type)
PPAR Alpha Agonists
Discontinued PPAR Alpha Agonists
Dual PPAR Alpha And Gamma Agonists
Discontinued Dual PPAR Alpha ? Gamma Agonists
Triple PPAR Alpha, Gamma & Delta (Pan) Agonists

Chapter IV: DPP-IV

DPP-IV
DPP-IV Discontinued or No Further Activities

Chapter V: GLP-1
Chapter VI: SGLT Inhibitors
Chapter VII: Emerging Diabetes Drugs
About la Merie Business Intelligence

The present Competitive Intelligence Report provides a competitor evaluation in the field of molecules used to treat diabetes as of March 2007

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos